Driving Positive Impact in Drug Development: tranScrip’s Commitment to ESG

At tranScrip, our commitment to Environmental, Social, and Governance (ESG) principles is not just a business strategy—it’s a core value that guides every aspect of our operations. By embedding ESG considerations into our daily practices, we aim to drive meaningful change, not only within our company but also in the broader pharmaceutical and biotech industries. Our ESG mission is clear: to enable our clients to maximise the value of their products for the benefit of patients worldwide, while contributing to a more sustainable, ethical, and socially responsible future. 

Environmental Stewardship 

In an industry where environmental impact might not be immediately apparent, tranScrip takes proactive steps to minimise its ecological footprint. We leverage digital platforms and virtual meetings to cut down on travel, significantly reducing carbon emissions. Our offices are energy-efficient, and we promote remote working to further decrease our environmental impact. By integrating these practices, tranScrip demonstrates that even in sectors not traditionally associated with high environmental impact, there is always room to operate more sustainably. 

Social Responsibility: Addressing Critical Health Needs 

tranScrip is particularly focused on supporting drug development for rare and underserved diseases—a commitment that aligns with the broader societal goal of improving public health. Our work is especially relevant in light of the recently published Women’s Health Strategy for England, which highlights the underrepresentation of women in clinical trials. By actively engaging in projects that target children’s and women’s health, infectious diseases, and orphan drugs, we are not only expanding access to vital treatments but also fostering inclusivity and innovation in drug development. 

Governance: Upholding the Highest Standards 

At tranScrip, we adhere to the highest standards of corporate governance, ensuring that our operations are transparent, ethical, and accountable. Our rigorous compliance mechanisms are designed to navigate the complex and highly regulated environment of drug development, ensuring that all projects meet or exceed regulatory standards. This approach builds trust with our clients and stakeholders, reinforcing our reputation for integrity and reliability. 

Key Achievements: A Testament to Our Commitment 

1. Significant Growth: Since our partnership with Palatine Private Equity, the number of drugs we have supported to achieve key development milestones has surged by 351%, far exceeding our Q4 2023 target. This growth underscores our ability to deliver high-quality results in a competitive industry.
2. Focus on Underserved Areas: Despite challenges in orphan drug development, we have increased our involvement in projects related to children’s and women’s health, infectious diseases, and orphan drugs by 27% in 2023. This focus highlights our commitment to addressing some of the most critical and underserved areas of healthcare.
3. Enhanced Climate Performance: We have significantly improved our climate impact by switching to renewable energy, now making up 75% of our energy use. Additionally, our commitment to low carbon operations, such as remote working and avoiding company-owned vehicles, further demonstrates our dedication to sustainability.
4. Sustainability Commitment: tranScrip has published a comprehensive ESG policy, reinforcing our dedication to sustainability across the company. We have also introduced regular climate change and environmental education initiatives for our employees, ensuring that sustainability is a shared responsibility and a key part of our corporate culture.

Conclusion: A Future Focused on Positive Change 

tranScrip’s unwavering dedication to ESG principles is reflected in our comprehensive approach to drug development and licensing. By minimising our environmental impact, focusing on socially responsible projects, and maintaining robust governance practices, we are not just meeting industry standards—we are setting new ones. Our commitment to developing treatments for rare and underserved diseases aligns with our mission to help clients maximise the value of their products, ultimately benefiting patients worldwide. In doing so, we continue to drive positive change, fostering a future where business success and societal impact go hand in hand.